Vivimed Labs Insolvency Petition
Vivimed Labs Limited, currently under CIRP, has scheduled the 8th meeting of the Committee of Creditors for September 29, 2026, via audio-visual means.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
14 announcements with these filters
Vivimed Labs Limited, currently under CIRP, has scheduled the 8th meeting of the Committee of Creditors for September 29, 2026, via audio-visual means.
Vivimed Labs is seeking a three-month extension from the Registrar of Companies to convene its Annual General Meeting for the financial year 2025-26.
Vivimed Labs Limited, currently under corporate insolvency resolution, has announced its 7th Committee of Creditors meeting scheduled for September 10, 2026, to be held virtually.
Vivimed Labs, undergoing CIRP, has scheduled the 6th meeting of the Committee of Creditors for August 18, 2026, as per regulatory requirements.
Vivimed Labs Ltd reported revenue from operations of ₹12 Cr (-53.1% YoY) and a net loss of ₹147.1 Cr for Q4 FY26.
Vivimed Labs scheduled a board meeting on July 17, 2026. The board will consider audited financial results for the period ending March 31, 2026.
Vivimed Labs replied to NSE's clarification request regarding financial results. The company submitted a revised Statement of Impact of audit qualifications.
Vivimed Labs Limited has postponed its board meeting originally scheduled for May 28, 2026. The meeting was intended to consider audited yearly financial results.
Vivimed Labs Ltd was fined ₹0.30 Crore by BSE and NSE for late financial results submission. The delay resulted from the CFO's resignation.
Vivimed Labs scheduled a board meeting on May 28, 2026, to approve audited financial results. This advance notice provides transparency on the upcoming earnings disclosure timeline.
Vivimed Labs scheduled a board meeting for May 28, 2026, to approve audited annual financial results. The trading window remains closed until May 31, 2026.
Vivimed Labs Limited has entered Corporate Insolvency Resolution Process (CIRP) following an NCLT Bengaluru Bench order dated April 15, 2026. T Narayana Swamy has been appointed as the Interim Resolution Professional. Creditors are called to submit claims by May 01, 2026, with an estimated resolution process closure date of October 11, 2026.
Vivimed Labs Limited has been admitted into the Corporate Insolvency Resolution Process (CIRP) by the NCLT, Bengaluru Bench. The action follows a petition by operational creditor Blue Cube Germany Assets GmbH over a ₹2.78 Crore default. Shri T Narayana Swamy has been appointed as the Interim Resolution Professional, and a moratorium has been declared.
Vivimed Labs Ltd has informed the exchanges that it is outside the purview of the 'Large Corporate' framework as per SEBI circular criteria. This routine regulatory disclosure confirms the company's classification regarding debt issuance and borrowing obligations for the upcoming period.